Information  X 
Enter a valid email address

Immupharma PLC (IMM)

  Print      Mail a friend       Annual reports

Thursday 01 November, 2018

Immupharma PLC

Nominated Adviser Status

RNS Number : 0704G
Immupharma PLC
01 November 2018


1 November 2018




ImmuPharma PLC

("ImmuPharma" or the "Company")


Nominated Adviser Status


ImmuPharma PLC (AIM: IMM.L), the specialist drug discovery and development company, announces that the Directors are aware of the proposed merger of its current nominated adviser ("NOMAD"), Northland Capital Partners ("Northland") with SP Angel Corporate Finance LLP. The Directors have also been informed that Northland has voluntarily agreed to relinquish its NOMAD status and will be removed from the register of NOMADs with effect from 7am (GMT) on 1 February 2019.


In accordance with AIM Rule 1, the Company is required to appoint a new NOMAD by 1 February 2019, if not, the Exchange will suspend trading in the Company's AIM Securities. If the Company does not appoint a replacement NOMAD by 4 March 2019, the admission of its AIM Securities will be cancelled. 


The Company has commenced the process to appoint a new NOMAD and will make a further announcement in due course.


This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 ("MAR").



For further information please contact:


ImmuPharma plc (

+ 44 (0) 20 7152 4080

Tim McCarthy, Chairman

Lisa Baderoon, Head of Investor Relations 

+ 44 (0) 7721 413496


Northland Capital Partners Limited (NOMAD & Joint Broker)
David Hignell, Dugald Carlean, Jamie Spotswood, Corporate Finance
Rob Rees, Corporate Broking


Stanford Capital Partners (Joint Broker)

Patrick Claridge

Chris Coleman


SI Capital (Joint Broker)                                                                     

Nick Emerson


+44 (0)20 3861 6625





+44 (0) 20 3815 8880



+44 (0) 1483 413500


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t